Identification

Name
Etodolac
Accession Number
DB00749  (APRD00067)
Type
Small Molecule
Groups
Approved, Investigational, Vet Approved
Description

Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.

Structure
Thumb
Synonyms
  • (+-)-1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid
  • (1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid
  • 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid
  • 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid
  • 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-ylacetic acid
  • Étodolac
  • Etodolac
  • Etodolaco
  • Etodolacum
  • Etodolic acid
  • Etodolsäure
External IDs
AY 24236
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EtodolacCapsule200 mgOralAa Pharma Inc1997-08-21Not applicableCanada
EtodolacCapsule300 mgOralAa Pharma Inc1997-08-21Not applicableCanada
Gen-etodolac 200mgCapsule200 mgOralGenpharm Ulc1999-01-122009-08-05Canada
Gen-etodolac 300mgCapsule300 mgOralGenpharm Ulc1999-01-122009-08-05Canada
Novo-etodolac 200 mgCapsule200 mgOralNovopharm LimitedNot applicableNot applicableCanada
Novo-etodolac 300 mgCapsule300 mgOralNovopharm LimitedNot applicableNot applicableCanada
Nu-etodolacCapsule200 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-etodolacCapsule300 mgOralNu Pharm IncNot applicableNot applicableCanada
Taro-etodolacCapsule300 mgOralTaro Pharmaceuticals, Inc.2000-10-20Not applicableCanada
Taro-etodolac 200 mgCapsule200 mgOralTaro Pharmaceuticals, Inc.2000-10-20Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EtodolacTablet, film coated, extended release500 mg/1OralPhysicians Total Care, Inc.2005-01-20Not applicableUs00093 7172 01 nlmimage10 6d05b6dd
EtodolacTablet, film coated, extended release500 mg/1OralGolden State Medical Supply2003-03-13Not applicableUs51672 4052 04 nlmimage10 35329a94
EtodolacTablet, film coated400 mg/1OralStat Rx USA2003-05-01Not applicableUs
EtodolacTablet, coated400 mg/1OralAmerincan Health Packaging2014-09-222016-03-31Us00185 0140 01 nlmimage10 5a33ad4d
EtodolacCapsule300 mg/1OralTaro Pharmaceuticals U.S.A., Inc.1998-04-30Not applicableUs
EtodolacTablet, film coated, extended release600 mg/1OralA S Medication Solutions2014-02-152017-06-20Us
EtodolacTablet, film coated500 mg/1OralA S Medication Solutions2003-05-012017-06-20Us
EtodolacTablet, coated500 mg/1OralPd Rx Pharmaceuticals, Inc.1999-04-192017-12-31Us
EtodolacTablet, film coated, extended release500 mg/1Oralbryant ranch prepack2000-08-11Not applicableUs
EtodolacCapsule300 mg/1OralGolden State Medical Supply1998-04-05Not applicableUs
International/Other Brands
Bodopine (Yuan Chou) / Dolarit (Drogsan) / Dolchis (Korea United Pharm) / Doloc (Unifarma) / Dualgan (ITF) / Eccoxolac (Meda) / Edolar Fort (Pfizer) / Edopain (Incepta) / Edopain ER (Incepta) / Elac (Royal) / Elderin (Lek) / Eric (U.C. Pharma) / Esodax (Münir Sahin) / ETL (Senton) / Etodin (Nobel) / Etodin Fort (Ulkar) / Etodol (Yuhan) / Etodon (Shinlon) / Etoflam (Standard Chem) / Etol Fort (Nobel) / Etolac (Alkaloid) / Etomax (Ipca) / Etomax-ER (Ipca) / Etonox (Charoen Bhaesaj) / Etopan (Winthrop Pharmaceuticals) / Etopin (U-Liang) / Lodine XL (Wyeth)
Categories
UNII
2M36281008
CAS number
41340-25-4
Weight
Average: 287.3535
Monoisotopic: 287.152143543
Chemical Formula
C17H21NO3
InChI Key
NNYBQONXHNTVIJ-UHFFFAOYSA-N
InChI
InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)
IUPAC Name
2-{1,8-diethyl-1H,3H,4H,9H-pyrano[3,4-b]indol-1-yl}acetic acid
SMILES
CCC1=C2NC3=C(CCOC3(CC)CC(O)=O)C2=CC=C1

Pharmacology

Indication

For acute and long-term management of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of pain.

Structured Indications
Pharmacodynamics

Etodolac is an anti-inflammatory agent with analgesic and antipyretic properties. It is used to treat osteoarthritis, rheumatoid arthritis and control acute pain. The therapeutic effects of etodolac are achieved via inhibition of the synthesis of prostaglandins involved in fever, pain, swelling and inflammation. Etodolac is administered as a racemate. As with other NSAIDs, the S-form has been shown to be active while the R-form is inactive. Both enantiomers are stable and there is no evidence of R- to S- conversion in vivo.

Mechanism of action

Similar to other NSAIDs, the anti-inflammatory effects of etodolac result from inhibition of the enzyme cycooxygenase (COX). This decreases the synthesis of peripheral prostaglandins involved in mediating inflammation. Etodolac binds to the upper portion of the COX enzyme active site and prevents its substrate, arachidonic acid, from entering the active site. Etodolac was previously thought to be a non-selective COX inhibitor, but it is now known to be 5 – 50 times more selective for COX-2 than COX-1. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
UProstaglandin G/H synthase 1
inhibitor
Human
URetinoic acid receptor RXR-alpha
other
Human
Absorption

Based on mass balance studies, the systemic bioavailability of etodolac from either the tablet or capsule formulation is at least 80%.

Volume of distribution
  • 390 mL/kg
Protein binding

> 99% bound, primarily to albumin

Metabolism

Etodolac is extensively metabolized in the liver. Renal elimination of etodolac and its metabolites is the primary route of excretion (72%). Metabolites found in urine (with percents of the administered dose) are: unchanged etodolac (1%), etodolac glucuronide (13%), hydroxylated metabolites (6-, 7-, and 8-OH; 5%), hydroxylated metabolite glucuronides (20%), and unidentified metabolites (33%). Fecal excretion accounts for 16% of its elimination.

Route of elimination

It is not known whether etodolac is excreted in human milk; however, based on its physical-chemical properties, excretion into breast milk is expected. Etodolac is extensively metabolized in the liver. The hydroxylated-etodolac metabolites undergo further glucuronidation followed by renal excretion and partial elimination in the feces (16% of dose). Approximately 1% of a etodolac dose is excreted unchanged in the urine with 72% of the dose excreted into urine as parent drug plus metabolite.

Half life

Terminal t1/2, 7.3 ± 4.0 hours. Distribution t1/2, 0.71 ± 0.50 hours

Clearance
  • Oral cl=49.1 mL/h/kg [Normal healthy adults]
  • Oral cl=49.4 mL/h/kg [Healthy males (18-65 years)]
  • Oral cl=35.7 mL/h/kg [Healthy females (27-65 years)]
  • Oral cl=45.7 mL/h/kg [Eldery (>65 years)]
  • Oral cl=58.3 mL/h/kg [Renal impairement (46-73 years)]
  • Oral cl=42.0 mL/h/kg [Hepatic impairement (34-60 years)]
Toxicity

Selective COX-2 inhibitors have been associated with increased risk of serious cardiovascular events (e.g. myocardial infarction, stroke) in some patients. Current data is insufficient to assess the cardiovascular risk of etodolac. Etodolac may increase blood pressure and/or cause fluid retention and edema. Risk of GI toxicity including bleeding, ulceration and perforation. Risk of direct renal injury, including renal papillary necrosis. Anaphylactoid and serious skin reactions (e.g. exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported. Common adverse events include abdominal pain, constipation, diarrhea, dyspepsia, flatulence, GI bleeding, GI perforation, nausea, peptic ulcer, vomiting, renal function abnormalities, anemia, dizziness, edema, liver function test abnormalities, headache, prolonged bleeding time, pruritus, rash, tinnitus. Symptoms of overdose include lethargy, drowsiness, nausea, vomiting, and epigastric pain.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Etodolac Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Etodolac is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Etodolac is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Etodolac is combined with 5-androstenedione.Experimental, Illicit
AbciximabEtodolac may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Etodolac can be decreased when combined with Abiraterone.Approved
AcebutololEtodolac may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Etodolac is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Etodolac is combined with Acemetacin.Approved
AcenocoumarolEtodolac may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Etodolac.Approved, Vet Approved
AclarubicinEtodolac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Etodolac.Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Etodolac.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Etodolac is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Etodolac is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Etodolac is combined with Alendronic acid.Approved
AliskirenEtodolac may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Etodolac is combined with Alminoprofen.Experimental
AlprenololEtodolac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Etodolac.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Etodolac is combined with Amcinonide.Approved
AmikacinEtodolac may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideEtodolac may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Etodolac can be decreased when combined with Amiodarone.Approved, Investigational
AmrubicinEtodolac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodEtodolac may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Etodolac is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Etodolac is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Etodolac is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Etodolac is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Etodolac is combined with Anisodamine.Investigational
annamycinEtodolac may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Etodolac is combined with Antipyrine.Approved
Antithrombin III humanEtodolac may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanEtodolac may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Etodolac is combined with Apocynin.Investigational
ApramycinEtodolac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Etodolac is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Etodolac can be increased when combined with Aprepitant.Approved, Investigational
ArbekacinEtodolac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinEtodolac may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanEtodolac may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololEtodolac may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Etodolac is combined with Atamestane.Investigational
AtenololEtodolac may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Etodolac is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etodolac.Approved
BalsalazideEtodolac may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminEtodolac may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Etodolac is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololEtodolac may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinEtodolac may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Etodolac.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Etodolac is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Etodolac.Approved
BenorilateThe risk or severity of adverse effects can be increased when Etodolac is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Etodolac is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Etodolac.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Betamethasone.Approved, Vet Approved
BetaxololEtodolac may decrease the antihypertensive activities of Betaxolol.Approved
BevantololEtodolac may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Etodolac is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Etodolac.Approved, Investigational
BisoprololEtodolac may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinEtodolac may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololEtodolac may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etodolac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Etodolac is combined with Bucillamine.Investigational
BucindololEtodolac may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Etodolac is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Etodolac is combined with Bufexamac.Experimental
BufuralolEtodolac may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Bumadizone.Experimental
BumetanideEtodolac may decrease the diuretic activities of Bumetanide.Approved
BupranololEtodolac may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Etodolac.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Etodolac.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Etodolac.Experimental
CapecitabineThe metabolism of Etodolac can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Etodolac.Approved
CarbamazepineThe metabolism of Etodolac can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Etodolac is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Etodolac.Approved
CarprofenThe risk or severity of adverse effects can be increased when Etodolac is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololEtodolac may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolEtodolac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Etodolac is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etodolac.Approved, Investigational
CeliprololEtodolac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Etodolac can be increased when it is combined with Ceritinib.Approved
CertoparinEtodolac may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Etodolac.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etodolac.Approved, Vet Approved
ChlorotrianiseneEtodolac may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Etodolac.Approved
CholecalciferolThe metabolism of Etodolac can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Etodolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Etodolac is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Etodolac is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etodolac.Approved
CinoxacinEtodolac may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the antiplatelet activities of Etodolac.Approved
Citric AcidEtodolac may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Etodolac is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Etodolac is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Etodolac is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Etodolac is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Etodolac.Vet Approved
CloranololEtodolac may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneEtodolac may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Etodolac can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Etodolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Etodolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensEtodolac may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Etodolac is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Etodolac is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Etodolac is combined with Cortisone acetate.Approved
CrisaboroleThe metabolism of Etodolac can be decreased when combined with Crisaborole.Approved
CurcuminThe risk or severity of adverse effects can be increased when Etodolac is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Etodolac.Experimental
CyclosporineEtodolac may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Etodolac is combined with D-Limonene.Investigational
Dabigatran etexilateEtodolac may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Etodolac can be decreased when it is combined with Dabrafenib.Approved
DaidzeinEtodolac may increase the thrombogenic activities of Daidzein.Experimental
DalteparinEtodolac may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidEtodolac may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the antiplatelet activities of Etodolac.Investigational
DarexabanEtodolac may increase the anticoagulant activities of Darexaban.Investigational
DaunorubicinEtodolac may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Etodolac is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Etodolac is combined with Deflazacort.Approved
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Etodolac.Experimental
DelavirdineThe metabolism of Etodolac can be decreased when combined with Delavirdine.Approved
DesirudinEtodolac may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Etodolac is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Etodolac is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Etodolac is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Etodolac is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Etodolac.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Etodolac is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Etodolac.Approved, Investigational
DextranEtodolac may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Etodolac may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Etodolac may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Etodolac may increase the anticoagulant activities of Dextran 75.Approved
DibekacinEtodolac may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Etodolac.Approved, Vet Approved
DicoumarolEtodolac may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolEtodolac may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolEtodolac may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Etodolac is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Etodolac is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Difluocortolone.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Etodolac is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Etodolac.Approved
DihydrostreptomycinEtodolac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Etodolac.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Etodolac.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Etodolac.Approved
DiphenadioneEtodolac may increase the anticoagulant activities of Diphenadione.Experimental
DosulepinThe metabolism of Etodolac can be decreased when combined with Dosulepin.Approved
DoxorubicinEtodolac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneEtodolac may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Etodolac is combined with Droxicam.Approved
DuloxetineDuloxetine may increase the antiplatelet activities of Etodolac.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Etodolac is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Etodolac is combined with E-6201.Investigational
Edetic AcidEtodolac may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEtodolac may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Etodolac can be decreased when combined with Efavirenz.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Etodolac.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Etodolac.Approved
EnoxacinEtodolac may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinEtodolac may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Etodolac.Experimental
EpanololEtodolac may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolEtodolac may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Etodolac is combined with Epirizole.Approved
EpirubicinEtodolac may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneEtodolac may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etodolac.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etodolac.Approved
EquileninThe risk or severity of adverse effects can be increased when Etodolac is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Etodolac is combined with Equilin.Approved
EquolEtodolac may increase the thrombogenic activities of Equol.Investigational
EscitalopramEscitalopram may increase the antiplatelet activities of Etodolac.Approved, Investigational
EsmololEtodolac may decrease the antihypertensive activities of Esmolol.Approved
EstradiolEtodolac may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
EstriolEtodolac may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedEtodolac may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneEtodolac may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Etodolac is combined with Estrone sulfate.Approved
Etacrynic acidEtodolac may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Etodolac.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Etodolac is combined with Ethenzamide.Experimental
Ethinyl EstradiolEtodolac may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateEtodolac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Etodolac is combined with Etidronic acid.Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etodolac is combined with Etofenamate.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Etodolac.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Etodolac is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Etodolac can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Etodolac is combined with Evening primrose oil.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when Etodolac is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Etodolac is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Etodolac is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Etodolac.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Etodolac.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Etodolac is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Feprazone.Experimental
Ferulic acidEtodolac may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Etodolac.Approved, Investigational
FleroxacinEtodolac may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Etodolac.Approved, Withdrawn
FloxuridineThe metabolism of Etodolac can be decreased when combined with Floxuridine.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Etodolac is combined with fluasterone.Investigational
FluconazoleThe metabolism of Etodolac can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Fludrocortisone.Approved
FluindioneEtodolac may increase the anticoagulant activities of Fluindione.Investigational
FlumequineEtodolac may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Etodolac is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Etodolac is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Etodolac is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Etodolac.Approved
FluorouracilThe metabolism of Etodolac can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the antiplatelet activities of Etodolac.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Etodolac.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Etodolac is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Etodolac.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Etodolac is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Etodolac can be decreased when combined with Fluvastatin.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Etodolac.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Etodolac.Approved, Nutraceutical, Vet Approved
FondaparinuxEtodolac may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumEtodolac may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Etodolac.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Etodolac is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Etodolac.Approved
FosphenytoinThe metabolism of Etodolac can be increased when combined with Fosphenytoin.Approved
FramycetinEtodolac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideEtodolac may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateEtodolac may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinEtodolac may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinEtodolac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Etodolac.Approved, Withdrawn
GemfibrozilThe metabolism of Etodolac can be decreased when combined with Gemfibrozil.Approved
GemifloxacinEtodolac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinEtodolac may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinEtodolac may increase the thrombogenic activities of Genistein.Investigational
GentamicinEtodolac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AEtodolac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Etodolac may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinEtodolac may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Etodolac is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Etodolac is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Etodolac is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Etodolac is combined with HE3286.Investigational
HeparinEtodolac may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolEtodolac may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Etodolac is combined with Higenamine.Investigational
HydralazineEtodolac may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Etodolac.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etodolac.Approved, Investigational
Hygromycin BEtodolac may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Etodolac is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Etodolac is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Etodolac is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Etodolac is combined with Icatibant.Approved
IdarubicinEtodolac may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxEtodolac may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etodolac.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Etodolac.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Etodolac is combined with Imidazole salicylate.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Etodolac.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Etodolac.Approved
IndenololEtodolac may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Etodolac can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Etodolac is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etodolac.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Etodolac is combined with Indoprofen.Withdrawn
INNO-206Etodolac may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe metabolism of Etodolac can be decreased when combined with Irbesartan.Approved, Investigational
IsepamicinEtodolac may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Etodolac is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Etodolac is combined with Istaroxime.Investigational
KanamycinEtodolac may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Etodolac can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Etodolac is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Etodolac.Approved
LabetalolEtodolac may decrease the antihypertensive activities of Labetalol.Approved
LandiololEtodolac may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Etodolac.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Etodolac.Approved, Investigational
LeflunomideThe metabolism of Etodolac can be decreased when combined with Leflunomide.Approved, Investigational
LepirudinEtodolac may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanEtodolac may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololEtodolac may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinEtodolac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Etodolac.Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Etodolac.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Etodolac.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Etodolac is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Etodolac.Approved
LobeglitazoneThe metabolism of Etodolac can be decreased when combined with Lobeglitazone.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Etodolac is combined with Lornoxicam.Approved, Investigational
LosartanThe metabolism of Etodolac can be decreased when combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Etodolac is combined with Loteprednol.Approved
LovastatinThe metabolism of Etodolac can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Etodolac is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Etodolac.Approved, Investigational
LumacaftorThe serum concentration of Etodolac can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Etodolac is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Etodolac.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Etodolac is combined with Magnesium salicylate.Approved
ManidipineThe metabolism of Etodolac can be decreased when combined with Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Etodolac.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Etodolac is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Etodolac is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Etodolac is combined with Mefenamic acid.Approved
MelagatranEtodolac may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Etodolac is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Etodolac is combined with Meloxicam.Approved, Vet Approved
MepindololEtodolac may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineEtodolac may increase the nephrotoxic activities of Mesalazine.Approved
MestranolEtodolac may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Etodolac is combined with Metamizole.Investigational, Withdrawn
MethallenestrilEtodolac may increase the thrombogenic activities of Methallenestril.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Etodolac.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Etodolac.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Methylprednisolone.Approved, Vet Approved
MetipranololEtodolac may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Etodolac.Approved
MetoprololEtodolac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideEtodolac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinEtodolac may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Etodolac can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Etodolac can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Etodolac.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Etodolac.Approved
MizoribineThe risk or severity of adverse effects can be increased when Etodolac is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Etodolac.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Etodolac.Approved
MoxestrolEtodolac may increase the thrombogenic activities of Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etodolac.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Etodolac is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Etodolac.Approved
NadololEtodolac may decrease the antihypertensive activities of Nadolol.Approved
NadroparinEtodolac may increase the anticoagulant activities of Nadroparin.Approved
NafamostatEtodolac may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Etodolac.Approved
Nalidixic AcidEtodolac may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Etodolac is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Etodolac is combined with NCX 1022.Investigational
NeamineEtodolac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololEtodolac may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Etodolac.Approved, Withdrawn
NemonoxacinEtodolac may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinEtodolac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Etodolac.Approved
NetilmicinEtodolac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe metabolism of Etodolac can be decreased when combined with Nicardipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Etodolac is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Etodolac is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Etodolac is combined with Nitroaspirin.Investigational
NorfloxacinEtodolac may increase the neuroexcitatory activities of Norfloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Etodolac is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etodolac.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Etodolac is combined with Olopatadine.Approved
OlsalazineEtodolac may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Etodolac is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Etodolac.Investigational
OmeprazoleThe metabolism of Etodolac can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Etodolac is combined with Orgotein.Vet Approved
OtamixabanEtodolac may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Etodolac is combined with Oxaprozin.Approved
Oxolinic acidEtodolac may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololEtodolac may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Oxyphenbutazone.Approved, Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Etodolac is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Etodolac is combined with Parecoxib.Approved
ParomomycinEtodolac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Etodolac.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Etodolac is combined with Parthenolide.Investigational
PazufloxacinEtodolac may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinEtodolac may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololEtodolac may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateEtodolac may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateEtodolac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Etodolac.Approved
PhenindioneEtodolac may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Etodolac can be increased when combined with Phenobarbital.Approved
PhenprocoumonEtodolac may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Etodolac can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etodolac.Approved, Investigational
PindololEtodolac may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidEtodolac may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinEtodolac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideEtodolac may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Pirfenidone.Approved, Investigational
Piromidic acidEtodolac may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etodolac.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Etodolac is combined with Pirprofen.Experimental
Platelet Activating FactorEtodolac may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinEtodolac may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinEtodolac may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Polyestradiol phosphateEtodolac may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Etodolac.Approved
PractololEtodolac may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Etodolac.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Etodolac is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Etodolac is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Etodolac is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Etodolac is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Pregnenolone.Experimental, Investigational
PrimidoneThe metabolism of Etodolac can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Etodolac can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Etodolac is combined with Proglumetacin.Experimental
PromestrieneEtodolac may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Etodolac is combined with Propacetamol.Approved, Investigational
PropranololEtodolac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Etodolac.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Etodolac.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Etodolac.Vet Approved
Protein CEtodolac may increase the anticoagulant activities of Protein C.Approved
Protein S humanEtodolac may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEtodolac may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinEtodolac may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Etodolac is combined with PTC299.Investigational
PuromycinEtodolac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Etodolac can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Etodolac.Approved, Investigational
QuinestrolEtodolac may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Etodolac.Approved
QuinineThe metabolism of Etodolac can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Etodolac.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Etodolac.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Etodolac is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinEtodolac may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinEtodolac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifampicinThe metabolism of Etodolac can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Etodolac can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Etodolac is combined with Risedronate.Approved, Investigational
RivaroxabanEtodolac may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Etodolac.Investigational, Withdrawn
RosoxacinEtodolac may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinEtodolac may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinEtodolac may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Etodolac.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Etodolac is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Etodolac is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Etodolac is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Etodolac.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Etodolac.Investigational
SecobarbitalThe metabolism of Etodolac can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolEtodolac may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Etodolac is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Etodolac is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Etodolac is combined with Serrapeptase.Investigational
SertralineSertraline may increase the antiplatelet activities of Etodolac.Approved
SildenafilThe metabolism of Etodolac can be decreased when combined with Sildenafil.Approved, Investigational
SisomicinEtodolac may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinEtodolac may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Etodolac.Approved
SorafenibThe metabolism of Etodolac can be decreased when combined with Sorafenib.Approved, Investigational
SotalolEtodolac may decrease the antihypertensive activities of Sotalol.Approved
SP1049CEtodolac may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinEtodolac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinEtodolac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Etodolac.Approved
SpironolactoneEtodolac may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Etodolac is combined with SRT501.Investigational
StreptomycinEtodolac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinEtodolac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfadiazineThe metabolism of Etodolac can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Etodolac can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Etodolac is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Etodolac can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Etodolac.Approved
SulodexideEtodolac may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Etodolac.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Etodolac is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Etodolac is combined with Suxibuzone.Experimental
Synthetic Conjugated Estrogens, AEtodolac may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BEtodolac may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusEtodolac may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Etodolac.Approved
TalinololEtodolac may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Etodolac.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Etodolac is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Etodolac.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Etodolac is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Etodolac is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Etodolac.Approved, Investigational
TemafloxacinEtodolac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Etodolac.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Etodolac is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Etodolac is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Etodolac.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Etodolac is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Etodolac is combined with Teriflunomide.Approved
TertatololEtodolac may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Etodolac is combined with Tiaprofenic acid.Approved
TiboloneEtodolac may increase the thrombogenic activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Etodolac can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Etodolac can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Etodolac is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololEtodolac may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Etodolac is combined with Tinoridine.Investigational
TioclomarolEtodolac may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Etodolac is combined with Tixocortol.Approved
TobramycinEtodolac may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolbutamideThe metabolism of Etodolac can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Etodolac is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etodolac.Approved
TopiroxostatThe metabolism of Etodolac can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideEtodolac may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Etodolac.Approved
TranilastThe risk or severity of adverse effects can be increased when Etodolac is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Etodolac.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Etodolac.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Etodolac is combined with Triamcinolone.Approved, Vet Approved
TriamtereneEtodolac may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Etodolac is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Etodolac.Approved, Vet Approved
TrimethoprimThe metabolism of Etodolac can be decreased when combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Etodolac is combined with Triptolide.Investigational
TrovafloxacinEtodolac may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinEtodolac may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Etodolac is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Etodolac.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Etodolac.Investigational, Withdrawn
Valproic AcidThe metabolism of Etodolac can be decreased when combined with Valproic Acid.Approved, Investigational
ValrubicinEtodolac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe metabolism of Etodolac can be decreased when combined with Valsartan.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Etodolac.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Etodolac.Approved
VoriconazoleThe metabolism of Etodolac can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinEtodolac may increase the anticoagulant activities of Warfarin.Approved
XimelagatranEtodolac may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Etodolac can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Etodolac is combined with Zaltoprofen.Approved, Investigational
ZeranolEtodolac may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Etodolac.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Etodolac.Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Etodolac.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Etodolac is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Etodolac is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinEtodolac may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinEtodolac may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Avoid alcohol.
  • Food increases the peak plasma concentration of extended-release tablets with no effect on extent of absorption.
  • Food increases the time to peak concentration of regular release oral formulations by 1.4 to 3.8 hours with no effect on extent of absorption.
  • Take with food to reduce gastric irritation.

References

Synthesis Reference

Christopher A. Demerson, Leslie G. Humber, "Process for preparing 1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)-indole-1-acetic acid, etodolac." U.S. Patent US4585877, issued May, 1977.

US4585877
General References
Not Available
External Links
Human Metabolome Database
HMDB14887
KEGG Drug
D00315
KEGG Compound
C06991
PubChem Compound
3308
PubChem Substance
46505184
ChemSpider
3192
BindingDB
50016799
ChEBI
4909
ChEMBL
CHEMBL622
Therapeutic Targets Database
DAP000778
PharmGKB
PA449550
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Etodolac
ATC Codes
M01AB08 — Etodolac
AHFS Codes
  • 28:08.04.92 — Other Nonsteroidal Antiimflammatory Agents
FDA label
Download (290 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentFasting3
1CompletedTreatmentHealthy Volunteers1
2Active Not RecruitingTreatmentProstatic Neoplasms1
3CompletedTreatmentAnkle Sprains1
3CompletedTreatmentPost Operative Pain1
3Not Yet RecruitingTreatmentPain, Acute1
3Unknown StatusPreventionNeoplasms, Colorectal1
4CompletedTreatmentMedicaments Substances in Therapeutic Use1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableUnknown StatusPreventionPrimary Operable Breast Cancer1

Pharmacoeconomics

Manufacturers
  • Aaipharma llc
  • Apotex inc
  • Endo pharmaceuticals inc
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Taro pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Wyeth pharmaceuticals inc
  • Point holdings inc
  • Watson laboratories inc florida
  • Actavis elizabeth llc
  • Apotex inc etobicoke site
  • Mylan laboratories inc
  • Ranbaxy laboratories ltd
Packagers
Dosage forms
FormRouteStrength
CapsuleOral200 mg
CapsuleOral200 mg/1
CapsuleOral300 mg/1
CapsuleOral300 mg
TabletOral400 mg/1
TabletOral500 mg/1
Tablet, coatedOral400 mg/1
Tablet, coatedOral500 mg/1
Tablet, extended releaseOral400 mg/1
Tablet, extended releaseOral500 mg/1
Tablet, extended releaseOral600 mg/1
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral500 mg/1
Tablet, film coated, extended releaseOral400 mg/1
Tablet, film coated, extended releaseOral500 mg/1
Tablet, film coated, extended releaseOral600 mg/1
Capsule, gelatin coatedOral300 mg/1
Prices
Unit descriptionCostUnit
Etodolac CR 600 mg 24 Hour tablet2.76USD tablet
Lodine 400 mg tablet2.65USD tablet
Lodine 500 mg tablet1.8USD tablet
Etodolac CR 500 mg 24 Hour tablet1.6USD tablet
Etodolac 500 mg tablet1.52USD tablet
Etodolac 400 mg tablet1.5USD tablet
Etodolac CR 400 mg 24 Hour tablet1.46USD tablet
Etodolac 300 mg capsule1.31USD capsule
Apo-Etodolac 200 mg Capsule0.8USD capsule
Apo-Etodolac 300 mg Capsule0.8USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)146.5 °CPhysProp
water solubility16 mg/LNot Available
logP2.5Not Available
pKa4.65Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0392 mg/mLALOGPS
logP3.39ALOGPS
logP3.44ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)4.73ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area62.32 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity81.16 m3·mol-1ChemAxon
Polarizability31.94 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9971
Blood Brain Barrier+0.9065
Caco-2 permeable+0.5726
P-glycoprotein substrateSubstrate0.7462
P-glycoprotein inhibitor INon-inhibitor0.9242
P-glycoprotein inhibitor IINon-inhibitor0.8988
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8545
CYP450 2D6 substrateNon-substrate0.7567
CYP450 3A4 substrateNon-substrate0.5
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6904
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9453
BiodegradationNot ready biodegradable0.9835
Rat acute toxicity3.4536 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9808
hERG inhibition (predictor II)Non-inhibitor0.7763
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000l-0090000000-cb5392bab35da402835e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0090000000-66382e8a032519cc0610
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0090000000-1ab9e4ff7d60e90eca2c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03di-0290000000-308131d28773ab2c9701
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-03dj-0890000000-ba74bd4789a5df9d1095
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-01pk-0920000000-3003d9d94ce99518b55e
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-0090000000-1644ab62d0cb24cc769e
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000f-0090000000-0d0a55600dd433d684b1
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-01ox-0090000000-17b2c48a871d73f3071a
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03di-0290000000-fe771b5ef7a99c3f79dd
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-03dj-0980000000-50aec638935d673b713e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0910000000-ca92c4a042f65a5a6c9e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0920000000-22f891e69de842afb76f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0910000000-3903a65f3f64f26aa9b7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-006x-0900000000-5bb09419198c9ca084c0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0900000000-61c0ea8a828fd0570b07
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0900000000-4bec68aee4ff03d6d386
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00dr-0890000000-e286df97fed2602fd759
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-0920000000-0323497d51f9000f512d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-0910000000-4c9034687504f43ca35d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-006x-1900000000-c7af982a125d43d0a322
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-1900000000-b6f0e91141ccbee49a24
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-00di-0930000000-16f06e354549b4eacb4c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00dr-0970000000-8693e29717fb7601dfab
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-0940000000-d9875ccdb5dd4639af09
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00dl-0910000000-c7918fc03d252733ba5b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0900000000-a45c507a9469f25641f1
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0900000000-c71c8b6e48beac782768
MS/MS Spectrum - , positiveLC-MS/MSsplash10-006x-2910000000-096819f066d468e77974

Taxonomy

Description
This compound belongs to the class of organic compounds known as indolyl carboxylic acids and derivatives. These are compounds containing a carboxylic acid chain (of at least 2 carbon atoms) linked to an indole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indolyl carboxylic acids and derivatives
Direct Parent
Indolyl carboxylic acids and derivatives
Alternative Parents
3-alkylindoles / Benzenoids / Pyrroles / Heteroaromatic compounds / Oxacyclic compounds / Monocarboxylic acids and derivatives / Dialkyl ethers / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds
show 4 more
Substituents
Indolyl carboxylic acid derivative / 3-alkylindole / Indole / Benzenoid / Pyrrole / Heteroaromatic compound / Oxacycle / Azacycle / Monocarboxylic acid or derivatives / Ether
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
monocarboxylic acid, organic heterotricyclic compound (CHEBI:4909)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Chen WS, Liu JH, Wei SJ, Liu JM, Hong CY, Yang WK: Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor. Cancer Sci. 2003 Mar;94(3):253-8. [PubMed:12824918]
  2. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK: Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer. 2001 Mar 15;91(6):894-9. [PubMed:11275997]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  4. Kusuhara H, Komatsu H, Sumichika H, Sugahara K: Reactive oxygen species are involved in the apoptosis induced by nonsteroidal anti-inflammatory drugs in cultured gastric cells. Eur J Pharmacol. 1999 Nov 3;383(3):331-7. [PubMed:10594327]
  5. Svendsen KB, Bech JN, Sorensen TB, Pedersen EB: A comparison of the effects of etodolac and ibuprofen on renal haemodynamics, tubular function, renin, vasopressin and urinary excretion of albumin and alpha-glutathione-S-transferase in healthy subjects: a placebo-controlled cross-over study. Eur J Clin Pharmacol. 2000 Aug;56(5):383-8. [PubMed:11009046]
  6. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Campbell NB, Jones SL, Blikslager AT: The effects of cyclo-oxygenase inhibitors on bile-injured and normal equine colon. Equine Vet J. 2002 Jul;34(5):493-8. [PubMed:12358053]
  2. Glaser K, Sung ML, O'Neill K, Belfast M, Hartman D, Carlson R, Kreft A, Kubrak D, Hsiao CL, Weichman B: Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol. 1995 Jul 25;281(1):107-11. [PubMed:8566109]
  3. Hirate K, Uchida A, Ogawa Y, Arai T, Yoda K: Zaltoprofen, a non-steroidal anti-inflammatory drug, inhibits bradykinin-induced pain responses without blocking bradykinin receptors. Neurosci Res. 2006 Apr;54(4):288-94. Epub 2006 Feb 13. [PubMed:16473424]
  4. Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Leger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Therien M, Wang Z, Webb JK, Wong E, Chan CC, et al.: Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105-17. [PubMed:9146894]
  5. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL: Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004 Jun;65(6):810-8. [PubMed:15198222]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Zinc ion binding
Specific Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expressi...
Gene Name
RXRA
Uniprot ID
P19793
Uniprot Name
Retinoic acid receptor RXR-alpha
Molecular Weight
50810.835 Da
References
  1. Kolluri SK, Corr M, James SY, Bernasconi M, Lu D, Liu W, Cottam HB, Leoni LM, Carson DA, Zhang XK: The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2525-30. Epub 2005 Feb 7. [PubMed:15699354]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein kinase c binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A10
Uniprot ID
Q9HAW8
Uniprot Name
UDP-glucuronosyltransferase 1-10
Molecular Weight
59809.075 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Mignot I, Presle N, Lapicque F, Monot C, Dropsy R, Netter P: Albumin binding sites for etodolac enantiomers. Chirality. 1996;8(3):271-80. [PubMed:8777148]
  2. Muller N, Lapicque F, Monot C, Payan E, Dropsy R, Netter P: Stereoselective binding of etodolac to human serum albumin. Chirality. 1992;4(4):240-6. [PubMed:1389961]
  3. Smith PC, Song WQ, Rodriguez RJ: Covalent binding of etodolac acyl glucuronide to albumin in vitro. Drug Metab Dispos. 1992 Nov-Dec;20(6):962-5. [PubMed:1362954]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Mulato AS, Ho ES, Cihlar T: Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther. 2000 Oct;295(1):10-5. [PubMed:10991954]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34